ANXA1 and brain ischemia: Data obtained in (150) provide new suggestion that appealing pro-resolving pharmacological approaches such as Annexin-A1 biomimetic peptides can effectively reduce neuro-inflammation and new data show a new multifaceted role for ANXA1 as a therapeutic and a prophylactic drug due to its capacity to stimulate endogenous pro-resolving, anti-thrombo-inflammatory circuits in cerebral ischemia–reperfusion injury (151).